Enzalutamide (MDV3100) – a New Drug from Medivation, can Increase Lifespan for Men with Terminal Prostate Cancer
Medivation is a San Francisco based pharmaceutical company that is not well known. However, this company is making the news with its experimental drug Enzalutamide (MDV3100). This drug was tested on about 1,200 patients with terminal prostate cancer.
It was shown that on the average, the lives of men with advanced prostate cancer were increased by 4.8 months. The report of the study is to be presented at the American Society of Clinical Oncology meeting in Chicago. Here are more details about this experimental drug from Medivation:
San Francisco-based Medivation doesn’t quite have the brand name recognition of its rivals in the world of prostate cancer drug development, but that could be starting to change, as soon as this weekend.
Medivation (NASDAQ: MDVN) has been on a big-time roll since November, when it released results from a study of 1,200 patients, called Affirm, that showed an experimental drug could extend the lives of men with terminal prostate cancer for a median time of 4.8 months compared with a placebo. Six months later, the drug is still generating buzz heading into this weekend’s big cancer drug confab, the American Society of Clinical Oncology. Investors can’t seem to get enough, as the stock has been on a truly spectacular run, climbing from a low of $14.32 to close at $85.01 a share yesterday.
While Medivation doesn’t have another earthshaking news update to provide on its drug at ASCO, it’s clear that this pill, and what it can do for prostate cancer patients, will be one of the hot topics of conversation at the big cancer meeting in Chicago. The burning question is whether Medivation and its partner Astellas Pharma can build on the early momentum, by winning FDA approval for its product enzalutamide (MDV3100), and whether it can show its drug also works for a larger group of prostate cancer patients with a less advanced form of the disease. If Medivation can do that—and most analysts are betting it will—then it will truly be on a collision course against marketed drugs from Seattle-based Dendreon (NASDAQ: DNDN) and New Brunswick, NJ-based Johnson & Johnson (NYSE: JNJ) that have shown an ability to prolong lives in the past couple of years.
Even though there is a lively ongoing debate about how aggressively to screen for prostate cancer, and whether widespread medical interventions cause more harm than good for this slow-moving malignancy, analysts still see a multi-billion dollar market emerging. About 30,000 men in the U.S. die from prostate cancer each year, according to the American Cancer Society. Click here for the full report.
Just as stated in the above extract, Medivation and its partners need to win the approval of the Food and Drug Administration (FDA) and also prove that this experimental drug can work for a larger population. If these are done, then this drug would be widely acceptable as one of the medications that would be recommended to treat cancer of the prostate that has become very aggressive or advanced.
Finally, the fact remain that tens of thousands of men in the US die from the condition every year. The American Cancer Society has reported this. Therefore, a drug like this, which is to be introduced by Medivation would a welcomed medication to extend and save the life many men affected by cancer of the prostate.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Cancer Drug New Prostate – New Drug for Prostate Cancer
- New Most Powerful Prostate Cancer Drug?
- Bayer New Prostate Cancer Drug
- Zytiga – New Prostate Cancer Drug From BTG
- New Drug KBU2046 To Contain Metastases of Prostate Cancer
- Prostate Cancer Drug Ban for NHS To Be Reversed By NICE
- Novel Drug Used on the Lockerbie Bomber Too Expensive for Prostate cancer Patients